GlassScriptPhysician profile
Nawal Shaikh
NPI 1003171091
$3,893.47
in general payments reported to CMS, 2019-2025
31 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $300 · 2021: $441 · 2022: $668 · 2023: $385 · 2024: $279 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Travel and Lodging: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.47 |
| Travel and Lodging | $866.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $1,531.24 | 2025 | Illuccix |
| Novocure INC. | $856.28 | 2019-2024 | Optune |
| Monteris Medical Corporation | $199.06 | 2022-2024 | Neuroblate |
| Abbvie INC. | $172.48 | 2021-2022 | |
| Sk Life Science, INC. | $133.84 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $125.14 | 2019-2022 | |
| Genzyme Corporation | $96.72 | 2020-2022 | |
| Ucb, INC. | $82.24 | 2020-2022 | |
| Tempus Ai, INC | $74.01 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $73.70 | 2021 | |
| Janssen Scientific Affairs, LLC | $66.69 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $65.62 | 2020-2022 | |
| Greenwich Biosciences, INC. | $36.42 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.96 | 2022 | |
| Merck Sharp & Dohme LLC | $32.27 | 2024 | Keytruda |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $32.14 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $27.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $25.29 | 2020-2021 | |
| Eisai INC. | $22.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.46 | 2020 | |
| Incyte Corporation | $19.35 | 2024 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $19.23 | 2021 | |
| Amgen INC. | $18.84 | 2021 | |
| Ns Pharma, INC. | $18.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.83 | 2024 | Libtayo |
| Merz Pharmaceuticals, LLC | $17.80 | 2022 | |
| Acadia Pharmaceuticals INC | $16.86 | 2022 | |
| Tesaro, INC. | $15.28 | 2019 | |
| Allergan, INC. | $14.42 | 2020 | |
| Foundation Medicine, INC. | $14.21 | 2023 | |
| Emd Serono, INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nawal Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.